Filtering by:
LymphomaLymphoma Survivor Becomes Nurse to Help Cancer Patients
When Crystal Zunino was diagnosed with non-Hodgkin lymphoma in January 2015, she was just half-way through her first year as a new middle-school math teacher in Warner Robins, Georgia.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
A Pioneer in Developing Drugs for People with T-Cell Lymphoma
Owen A. O'Connor, MD, PhD, was awarded the prestigious American Cancer Society Clinical Research Professor grant in July 2018. He was selected because of his expertise and ongoing work to develop drugs to improve treatments for people with Hodgkin and non-Hodgkin lymphomas. He's a professor and researcher at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York, New York.
Caring for Children with Cancer
The types of cancers that develop in children are often different from the types that develop in adults. Even when kids have a cancer type that adults get too, it is often treated differently.
FDA Approves Poteligeo (Mogamulizumab) for Lymphoma of the Skin
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.
FDA Approves Calquence (Acalabrutinib) for Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has approved a targeted therapy for treating certain adults with mantle cell lymphoma.
FDA Approves Yescarta (Axicabtagene Ciloleucel) for Adults with Certain Lymphomas
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell lymphoma.
